Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-30. (cancelled)

31. (previously presented) A method of treating anxiety comprising administering to a subject in need of such treatment a therapeutically effective amount of a mGluR5 antagonist.

32. (previously presented) A method according to Claim 31 wherein the mGluR5 antagonist is selected from the group consisting of 2-arylalkenyl-pyridines, 2-heteroarylalkenyl-pyridines, 2-arylalkynyl-pyridines, 2-heteroaryl-alkynyl-pyridines, 2-arylazo-pyridines and 2-heteroarylazo-pyridines, in free base form or in pharmaceutically acceptable salt form.

33. (currently amended) A method according to Claim 31 wherein the mGluR5 antagonist is a compound of formula I



(I)

wherein

R_1 is hydrogen, (C_{1-4})alkyl, (C_{1-4})alkoxy, cyano, ethynyl or di(C_{1-4})alkylamino;

R_2 is hydrogen, hydroxy, carboxy, (C_{1-4})alkoxycarbonyl, di(C_{1-4})alkylaminomethyl, 4-(4-fluoro-benzoyl)-piperidin-1-yl-carboxy, 4-*t*-butyloxycarbonyl-piperazin-1-yl-carboxy, 4-(4-azido-2-hydroxybenzoyl)-piperazin-1-yl-carboxy or 4-(4-azido-2-hydroxy-3-iodo-benzoyl)-piperazin-1-yl-carboxy;

R_3 is hydrogen, (C_{1-4})alkyl, carboxy, (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbamoyl, hydroxy(C_{1-4})alkyl, di(C_{1-4})alkylaminomethyl, morpholinocarbonyl or 4-(4-fluorobenzoyl)-piperidin-1-yl-carboxy;

R_4 is hydrogen, hydroxy, carboxy, (C_{2-5})alkanoyloxy, (C_{1-4})alkoxycarbonyl, amino(C_{1-4})alkoxy, di(C_{1-4})alkylamino(C_{1-4})alkoxy, di(C_{1-4})alkylamino(C_{1-4})alkyl or hydroxy(C_{1-4})alkyl; and

R_5 is a group of formula



wherein

R_a and R_b, independently, are hydrogen, halogen, nitro, cyano, (C_{1-4})alkyl, (C_{1-4})alkoxy, trifluoromethyl, trifluoromethoxy or (C_{2-5})alkynyl; and

R_c is hydrogen, fluorine, chlorine, bromine, hydroxy(C_{1-4})alkyl, (C_{2-5})alkanoyloxy, (C_{1-4})alkoxy or cyano; and

R_d is hydrogen, halogen or (C_{1-4})alkyl;

in free base form or in pharmaceutically acceptable salt form.

34. (previously presented) A method according to claim 31 wherein the mGluR5 antagonist is selected from the group consisting of 2-[2-(pyridin-3-yl)ethenyl]-6-methyl-pyridine, 3-methoxy-6-methyl-2-m-tolylethynyl-pyridine, 2-methyl-6-(2,3,5-trichloro-phenylethynyl)-pyridine, 2-methyl-6-(phenylethynyl)-pyridine and 2-(3-fluoro-phenylethynyl)-6-methyl pyridine.